Highlights Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
17.68 ^USD	+1.38%		-15.37%	+61.61%

05-10	Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating	MT
05-09	Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial	05-06	MT
Edgewise Therapeutics, Inc Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy	05-06	CI
Sector Update: Health Care Stocks Mixed Premarket Tuesday	04-16	MT
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	04-15	MT
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	04-15	CI
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	03-28	CI
Edgewise Therapeutics Full Year 2023 Net Loss Widens	02-22	MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Edgewise Therapeutics Drug Candidate to Treat Duchenne Gets FDA's Fast Track Designation	02-13	MT
Edgewise Shares Rise Premarket on FDA Fast-Track Designation	02-13	DJ
Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	02-13	CI
Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA	11-30	CI
Edgewise Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Edgewise Therapeutics Announces Expansion of Their Edg-5506 Clinical Program in Duchenne Muscular Dystrophy	23-10-26	CI
Edgewise Therapeutics, Inc. Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy	23-09-26	CI
Edgewise Therapeutics, Inc. Begins Dosing First-In-Human Phase 1 Trial of EDG-7500	23-09-14	CI
Edgewise Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Edgewise Therapeutics, Inc. Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy	23-06-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Highlights

Filters